In 2003, Mr. Adam accepted his position as the advisor of MediBIC for global business development strategy. In 1994, Mr. Adam became Director, Commercial Strategy Glaxo plc, following his career as President of the French organization of Glaxo. In 1997, he accepted a position as Regional Director Japan and was also a global board member of GlaxoWellcome.

 Dr. Horie accepted his position as Scientific Advisor of MediBIC in August, 2002. He first joined Eisai Co., Ltd. and gained experience as a researcher in the Pharmacology and Drug Metabolism Laboratory and Pharmacokinetics Laboratory. He was then promoted to Head of Drug Discovery Metabolism Research Institute, Drug Discovery Division.
  After leaving Eisai, he established D-Three Institute, providing education and training opportunities to pharmaceutical researchers, as well as consultation in the field of drug discovery and pharmacokinetics studies.

  Mr.Yoshida first joined MediBIC as a statutory auditor from January 2002 to March 2005. He then became an advisor of MediBIC in April 2005 and from 2006, he became one of the advisory board members. His previous experiences are Chief Researcher, Tokyo Research Laboratories, Managing Officer of R&D Head Office, and Corporate Research Strategy Offcer, KYOWA HAKKO KOGYO CO., LTD., Director, Kyowa Medex Co., Ltd.

Yoshitada Notsu, Ph.D.
Scientific Advisor, MediBIC Group

  Dr.Notsu joined MediBIC Group in February 2005. Following his position as Managing Director, R&D Strategic Planning, he accepted his current position as Scientific Advisor of MediBIC Group from July 2007.
  In the past, Dr. Yoshitada Notsu was assigned to the Research and Development Department of Fujisawa Pharmaceutical Co., Ltd. (currently Astellas Pharma Inc ) . At the Dr. J. Axelrod laboratory of NIH (USA), he was involved with research on biochemical/ pharmacological studies of the protein factor. He was also a chief scientist of the R&D Department where he engaged in researching various disorders and was resposible for project management as a vice-director of Exploratory Research Laboratories in Tsukuba. Afterwards, he moved to Director of Molecular Biology Division of Fujisawa Exploratory Research Laboratories.
  At the Fujisawa US subsidiary, he engaged in the investment operation towards venture companies, and assessed more than 100 companies as a scientific reviewer. He was also in charge of licensing at the Management Strategic Division of Fujisawa Pharmaceutical Co., Ltd followed by a position as Board Member and Director of Research Laboratories at a middle-sized pharmaceutical company.